Tweet

European Approval For Intramuscular Administration Route Of NUFLOR Minidose

Author: FOUR PAWS
Posted: Thursday 16th June, 2011. 13:28:29

June 16, 2011 – Intervet/Schering-Plough Animal Health announced today that it has recently received approval via the decentralized procedure in the European Union for the intramuscular (IM) route of administration of NUFLOR® Minidose 450 mg/mL, a florfenicol-containing broad-spectrum antibiotic for the management of bovine respiratory disease (BRD).

NUFLOR Minidose was approved initially in 2008 for subcutaneous (SC) use only and the now approved IM administration route is a line extension. IM administration (20 mg/kg administered twice, 48h apart) offers additional flexibility for the veterinarian when treating cattle for BRD. NUFLOR Minidose is the florfenicol injectable formulation which offers the lowest injection volume, which in particular is practical when treating heavier animals (thereby avoiding large injection volumes). Furthermore, the withdrawal period after IM administration of NUFLOR Minidose is only 37 days and is considerably shorter as compared to 64 days after SC use (40 mg/kg body weight injected once).

“Our customers requested the IM claim when NUFLOR Minidose was first introduced and we are delighted to be able to recommend this route of administration hence forth” says Francis Adriaens, Global Marketing Director, Global Ruminants Business Unit at Intervet/Schering-Plough Animal Health.

NUFLOR Minidose is indicated for preventive and therapeutic treatment of BRD in cattle caused by Mannheimia haemolytica, Pasteurella multicoda and Histophilus somni susceptible to florfenicol. The presence of the disease in the herd should be confirmed before administering preventive treatment.

BRD is a devastating disease in cattle and is most often associated with the assembly of large groups of cattle from diverse origins. Many factors including stress and transport play a role in BRD. The most important infectious agents involved are Mannheimia haemolytica and, less commonly, Pasteurella multocida or Histophilus somni. The disease is of considerable economic significance to producers, and can be responsible for a high mortality rate and the condemnation of infected carcasses at slaughter.

This article has been viewed 890 times.

 

Comments about this article